Grace Therapeutics (GRCE) Price to Book (2017 - 2026)

Grace Therapeutics has disclosed Price to Book across 10 years of filings, most recently posting 0.77 for Q2 2026.

• In Q2 2026, Price to Book rose 18.57% year-over-year to 0.77; the TTM figure through Jun 2026 stood at 0.77 (up 18.57% YoY), while the FY2026 annual figure was 1.16, up 147.28% from the prior year.
• Price to Book came in at 0.77 for Q2 2026 at Grace Therapeutics, down from 1.16 in the prior quarter.
• In the past five years, Price to Book ranged from a high of 1.16 in Q1 2026 to a low of 0.23 in Q4 2022.
• Average Price to Book over 5 years is 0.53, with a median of 0.48 recorded in 2024.
• Year-over-year, Price to Book plunged 83.21% in 2022 and soared 147.28% in 2026.
• Over 5 years, Price to Book stood at 0.23 in 2022, then jumped by 82.1% to 0.42 in 2023, then soared by 73.19% to 0.73 in 2024, then climbed by 13.44% to 0.83 in 2025, then dropped by 7.13% to 0.77 in 2026.
• Per Business Quant data, the three most recent Price to Book figures were 0.77 in Q2 2026, 1.16 in Q1 2026, and 0.83 in Q4 2025.